



**CORRELATION BETWEEN CT GUIDED  
PULMONARY ARTERY DIAMETER AND  
RIGHT VENTRICULAR FUNCTION BY  
ECHOCARDIOGRAPHY IN PULMONARY  
HYPERTENSION PATIENTS**

Thesis

Submitted For partial fulfillment of Master Degree in chest  
diseases and tuberculosis

By

**Ahmed Mohamed Abd Elsamad**

*M.B.B.Ch*

Supervised By

***Prof. Mohamed Ali Farrag***

Prof .of chest diseases and tuberculosis

***Dr. Hala Mohamed Salem***

Assist. Prof of chest diseases and tuberculosis

***Dr. Ahmed Mohamed Elmahmoudy***

Assist. Prof of cardiology

Faculty of Medicine

Ain Shams University

2015

# LIST OF CONTENTS

Title	page
• Introduction.....	1
• Aim of the work .....	4
• Review of literature:	
- Chapter 1: Pulmonary hypertension.....	7
-Chapter 2: Role of CT in diagnosis of pulmonary hypertension.....	33
-Chapter 3: Echocardiographic assessment of pulmonary hypertension.....	58
• Patients and methods.....	84
• Results.....	91
• Discussion.....	103
• Summary.....	114
• Conclusion.....	117
• Recommendations.....	119
• References.....	121
• Arabic summar	

## • **LIST OF TABLES**

<b><i>Table no.</i></b>	<b><i>Title</i></b>	<b><i>page</i></b>
<b><i>Table 1</i></b>	<b><i>Updated Clinical Classification of Pulmonary Hypertension.</i></b>	<b><i>9</i></b>
<b><i>Table 2</i></b>	<b><i>Determinants of Prognosis of PAH.</i></b>	<b><i>25</i></b>
<b><i>Table 3</i></b>	<b><i>Differential Diagnostic CT Features of Pulmonary hypertension.</i></b>	<b><i>34</i></b>
<b><i>Table 4</i></b>	<b><i>Heath and Edwards System for Grading the Severity of Vascular Changes in Pulmonary Arterial Hypertension.</i></b>	<b><i>49</i></b>
<b><i>Table 5</i></b>	<b><i>Parameters affected by pulmonary hypertension that can be detected by right heart imaging.</i></b>	<b><i>62</i></b>
<b><i>Table 6</i></b>	<b><i>Effect of pulmonary hypertension on measurements from tissue Doppler imaging.</i></b>	<b><i>67</i></b>
<b><i>Table 7</i></b>	<b><i>Estimation of right atrial pressure from the inferior vena cava .</i></b>	<b><i>70</i></b>

<b>Table 8</b>	<b><i>Right ventricular pressure, cavity and functional measurements that may indicate pulmonary hypertension.</i></b>	<b>73</b>
<b>Table 9</b>	<b><i>Demographic criteria of the whole patients.</i></b>	<b>92</b>
<b>Table 10</b>	<b><i>Demographic distribution among the four studied groups of pulmonary hypertension.</i></b>	<b>94</b>
<b>Table 11</b>	<b><i>Correlations of Pulmonary artery diameter with RVSP.</i></b>	<b>95</b>
<b>Table 12</b>	<b><i>Correlations of Pulmonary artery diameter with MPI.</i></b>	<b>95</b>
<b>Table 13</b>	<b><i>Sensitivity of pulmonary artery diameter as a predictor for PH.</i></b>	<b>96</b>
<b>Table 14</b>	<b><i>Correlation of P/A ratio with RVSP.</i></b>	<b>97</b>
<b>Table 15</b>	<b><i>Correlation between P/A ratio to MPI.</i></b>	<b>98</b>

<b>Table 16</b>	<b><i>Demographic data of the studied cases according to MPI.</i></b>	<b>99</b>
<b>Table 17</b>	<b><i>Assessment of MPI in relation to pulmonary artery diameter and RVSP.</i></b>	<b>99</b>
<b>Table 18</b>	<b><i>Sensitivity and Specificity of RVSP in relation to MPI.</i></b>	<b>100</b>
<b>Table 19</b>	<b><i>comparison between the 4 classified groups of pulmonary hypertension.</i></b>	<b>101</b>

•  
•

## ***LIST OF FIGURES***

<b><i>Figure no.</i></b>	<b><i>Title</i></b>	<b><i>Page</i></b>
<b><i>Figure 1</i></b>	<b><i>The recommend approach for diagnosis of pulmonary hypertension.</i></b>	<b><i>20</i></b>
<b><i>Figure 2</i></b>	<b><i>Recent treatment guideline for pulmonary hypertension.</i></b>	<b><i>25</i></b>
<b><i>Figure 3</i></b>	<b><i>Different views for right ventricle by echocardiography.</i></b>	<b><i>60</i></b>
<b><i>Figure 4</i></b>	<b><i>Measurement of the peak tricuspid regurgitant velocity, pulmonary regurgitant velocity, Acceleration time and Right atrial pressure.</i></b>	<b><i>70</i></b>
<b><i>Figure 5</i></b>	<b><i>Measurement of the right atrial area, right atrial volume, left ventricular eccentricity index</i></b>	<b><i>76</i></b>
<b><i>Figure 6</i></b>	<b><i>Measurement of myocardial performance index (MPI) using tissue Doppler imaging and Measurement of tricuspid annular plane systolic excursion (TAPSE).</i></b>	<b><i>78</i></b>
<b><i>Figure 7</i></b>	<b><i>An algorithm for investigating pulmonary hypertension (PH) using echocardiography</i></b>	<b><i>83</i></b>
<b><i>Figure 8</i></b>	<b><i>How to calculate MPI</i></b>	<b><i>88</i></b>
<b><i>Figure 9</i></b>	<b><i>How to measure pulmonary artery diameter in CT chest</i></b>	<b><i>89</i></b>

## **LIST OF ABBREVIATIONS**

<b>AT</b>	<b>.....Acceleration time</b>
<b>EF</b>	<b>..... Ejection fraction</b>
<b>ET</b>	<b>..... Ejection time</b>
<b>FAC</b>	<b>..... Fractional area change</b>
<b>IVA</b>	<b>..... Isovolumic acceleration</b>
<b>IVC</b>	<b>..... Inferior vena cava</b>
<b>IVCT</b>	<b>..... Isovolumic contraction time</b>
<b>IVRT</b>	<b>.....Isovolumic relaxation time</b>
<b>MPI</b>	<b>..... Myocardial performance index</b>
<b>MRI</b>	<b>..... Magnetic resonance imaging</b>
<b>LV</b>	<b>.....Left ventricle</b>
<b>PA</b>	<b>.....Pulmonary artery</b>
<b>PADP</b>	<b>..... Pulmonary artery diastolic pressure</b>
<b>PH</b>	<b>.....Pulmonary hypertension</b>
<b>PLAX</b>	<b>..... Parasternal long-axis</b>
<b>PSAX</b>	<b>..... Parasternal short-axis</b>
<b>PVR</b>	<b>.....Pulmonary vascular resistance</b>
<b>RA</b>	<b>.....Right atrium</b>
<b>RIMP</b>	<b>..... Right ventricular index of myocardial performance</b>

**RV ..... Right ventricle**  
**RVH ..... Right ventricular hypertrophy**  
**RVOT ..... Right ventricular outflow tract**  
**RVSP ..... Right ventricular systolic pressure**  
**SD ..... Standard deviation**  
**SPAP .....Systolic pulmonary artery pressure**  
**TAM ..... Tricuspid annular motion**  
**TAPSE ..... Tricuspid annular plane systolic excursion**  
**3D ..... Three-dimensional**  
**TR ..... Tricuspid regurgitation**  
**2D .....Two-dimensional**  
**P/A .....pulmonary artery diameter/aortic diameter**  
**PAH.....Pulmonary arterial hypertension**  
**NO.....nitric oxide**  
**CTEPH .....chronic thromboembolic PAH**



# **INTRODUCTION**

## **Introduction**

Pulmonary hypertension is defined as a resting mean pulmonary arterial pressure of 25 mmHg or greater at right heart catheterization, this is a hemodynamic feature that is shared by all types of pulmonary hypertension in the Dana Point classification system. A resting mean pulmonary arterial pressure of 20mmHg or less is considered normal, while mean pulmonary arterial pressures ranging between 21-24 mmHg is considered abnormal requiring further investigation about the clinical course of disease (45).

Pulmonary hypertension may primarily affect either the arterial (precapillary) or the venous (postcapillary) pulmonary circulation. Pulmonary arterial hypertension may be idiopathic or arise in association with chronic pulmonary thromboembolism; pulmonary embolism caused by tumor cells, parasitic material, or foreign material; parenchymal lung disease; liver disease; vasculitis; human immunodeficiency virus infection; or a left-to-right cardiac shunt. Its histologic characteristics include vascular changes-medial hypertrophy, intimal cellular proliferation, intraluminal thrombosis, and the development of plexiform lesions-that manifest primarily in the muscular pulmonary arteries. Features of pulmonary arterial hypertension that may be seen at computed tomography (CT) are central pulmonary artery dilatation, abrupt narrowing or tapering of peripheral pulmonary vessels, right ventricular hypertrophy, right ventricular and atrial enlargement, dilated bronchial arteries, and a mosaic pattern of attenuation due to variable lung perfusion (12)

CT-determined mean pulmonary artery diameter has excellent diagnostic value for detection of PH in patients with advanced lung disease. Therefore, standard chest CT scans can be used to screen for PH as a cause of exertional limitation in patients with

parenchymal lung disease. Because CT is commonly used to evaluate parenchymal lung disease, this information is readily available (34).

In noncontrast multi-detector computed tomography (CT), both main pulmonary artery (mPA) diameter and ratio of the mPA to the ascending aorta (ratio PA) measurements are easily obtained and highly reproducible. This simple measurement of axial mPA diameter at the level of the bifurcation of the right pulmonary artery is easy to define anatomically. The ascending aorta can be simultaneously measured to provide a quick calculation of the ratio PA. The Framingham Heart Study showed that the normal reference sex-specific CT cutoff value for mPA for men is 29 mm and for women is 27 mm and for ratio PA is 0.9 for both men and women. These 2 simple measurements may hold some promise for the preclinical diagnosis for the “silent diseases” of the cardiopulmonary system (186).

Severity of symptoms and survival in patients with pulmonary artery hypertension are strongly associated with right ventricular function, and right heart failure is the main cause of death in patients with PAH. Echocardiography and cardiac magnetic resonance imaging allow noninvasive evaluation of right ventricular function and structure .Simple, reproducible, noninvasive measures of right ventricular function would help to improve the management of patients with PAH, and to provide tools with which to help establish the optimal therapeutic approach to manage not only the effects of the disease on the pulmonary vasculature, but also to support and improve right ventricular function (18).

## **AIM OF THE WORK**

## Aim of the work ;

To correlate between the pulmonary artery diameter or its ratio to aortic diameter in CT chest and right ventricular function measured by echocardiography in pulmonary hypertension patients.

# **REVIEW OF LITERATURE**

## Chapter one

### **Pulmonary hypertension**

Pulmonary hypertension (PH) is defined as a hemodynamic and pathophysiological condition characterized by an increase in mean pulmonary arterial pressure ( $P_{pa}$ ) to  $\geq 25$  mmHg at rest as measured by right heart catheterization (RHC).(1)

Because this definition is based on hemodynamic criteria, pulmonary hypertension can be the result of a variety of diseases of different causes. Pulmonary arterial hypertension (PAH), however, should be distinctly differentiated from pulmonary venous hypertension resulting from left heart disease. PAH is characterized by elevations in the pulmonary arterial pressure and pulmonary vascular resistance (PVR) leading to right ventricular failure and premature death. (2)

Thus, the definition of PAH also requires normal pulmonary artery occlusion (or wedge) pressure to exclude elevations of pulmonary artery pressure simply as a compensation for elevated pressures in the left heart. PAH is commonly caused by or associated with an underlying pulmonary, cardiac or systemic disease (associated PAH [APAH], previously known as secondary pulmonary hypertension). Rarely, PAH is present in the absence of an identifiable cause or associated underlying disease and is referred to as idiopathic PAH (IPAH) or primary PAH (PPH). A familial form of IPAH (FPAH) accounts for about 6% of cases.(2)

The small case series on elevated pulmonary artery pressures in otherwise healthy young individuals in the 1950s and 1960s and the epidemic of anorexigenic-associated PAH in Europe led to the first World Health Organization (WHO) conference on PPH in 1973.(3)